SCHEMBL6640586

SCHEMBL6640586

COc1cc(CC(=O)NC[C@H]2CC[C@@H](N)C2)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.49
▸ MAPK1 P28482 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ LMNA P02545 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ CCNT1 O60563 1/20 0.44
▸ CCNE1 P24864 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ CDK9 P50750 1/20 0.44
▸ CDK5 Q00535 1/20 0.44
▸ CDK5R1 Q15078 1/20 0.44
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ HTT P42858 1/20 0.43
▸ MAPK10 P53779 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6640588 1.00 ALDH1A1 (0.49) ALDH1A1MAPK1SMN1; SMN2TDP1LMNA
SCHEMBL6640992 0.86 ALDH1A1 (0.47) ALDH1A1MAPK1SMN1; SMN2TDP1LMNA
SCHEMBL6643674 0.83 TDP1 (0.69) ALDH1A1MAPK1SMN1; SMN2TDP1KMT2A
SCHEMBL6640472 0.83 TDP1 (0.69) ALDH1A1MAPK1SMN1; SMN2TDP1KMT2A
SCHEMBL6640837 0.79 SMN1; SMN2 (0.48) ALDH1A1MAPK1SMN1; SMN2TDP1LMNA
SCHEMBL6640831 0.79 SMN1; SMN2 (0.48) ALDH1A1MAPK1SMN1; SMN2TDP1LMNA
SCHEMBL6639898 0.76 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1KDM4EKMT2A
SCHEMBL6639904 0.76 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1KDM4EKMT2A
SCHEMBL6639136 0.76 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1KDM4EKMT2A
SCHEMBL6639133 0.76 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 — — EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 — — US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 — — US disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 ALDH1A1 208/4885MAPK1 1001/4885SMN1; SMN2 4263/4885
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ABCC1, ABCB11, ABCB1 ALDH1A1 264/4885MAPK1 1431/4885SMN1; SMN2 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback